In preclinical models it potentiated cisplatin and irradiation, particularly in ATM-deficient settings, by preventing G2 arrest and repair and forcing lethal mitosis; combinations with cisplatin or topotecan produced deeper tumor regressions than chemotherapy alone [95–97]. The gene discussed is ATM; the disease is neoplasm.